NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
16 trialsNCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT06754501 2026-02-18
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT04759248 2025-09-09
ATREZZO
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT03108131 2025-05-28
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04602078 2025-04-24
AUREA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03708224 2025-01-28
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of California, San Francisco
Phase 2 Recruiting
NCT03164993 2024-10-15
ALICE
Oslo University Hospital
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT03767075 2024-04-25
BoB
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02458638 2021-06-04
A Study of Atezolizumab in Advanced Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed